excessive saliva production; Severe whole body muscle pain for two weeks; still experiencing  persistent sweating 24/7; skin irritation due to sweating; constipation; incontinence when rising to stand and walking; high wbc; leg weakness; constant random muscle twitching spasms; pins and needles hands and feet,tingling in extremities; Ice cold extremities; elevated heart rate 105+; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 64 year-old female patient (not pregnant) received bnt162b2 (BNT162B2), administered in arm left, administration date 25Apr2021 11:00 (Lot number: EW0161) at the age of 64 years as dose 2, single for covid-19 immunisation. Relevant medical history included: "Thymoma cancer 2005", start date: 2005 (unspecified if ongoing), notes: Thymoma cancer 2005, recurring 10Jun2021. There were no concomitant medications. Past drug history included: Morphine, reaction(s): "Known Allergy: Morphine". Vaccination history included: Bnt162b2 (lot number: ER8734, dose number: 1, vaccine location: Left arm), administration date: 05Apr2021, when the patient was 64 years old, for COVID-19 Immunisation. The following information was reported: SALIVARY HYPERSECRETION (non-serious) with onset 26Apr2021 20:00, outcome "not recovered", described as "excessive saliva production"; MYALGIA (non-serious) with onset 26Apr2021 20:00, outcome "not recovered", described as "Severe whole body muscle pain for two weeks"; HYPERHIDROSIS (non-serious) with onset 26Apr2021 20:00, outcome "not recovered", described as "still experiencing  persistent sweating 24/7"; SKIN IRRITATION (non-serious) with onset 26Apr2021 20:00, outcome "not recovered", described as "skin irritation due to sweating"; CONSTIPATION (non-serious) with onset 26Apr2021 20:00, outcome "not recovered", described as "constipation"; INCONTINENCE (non-serious) with onset 26Apr2021 20:00, outcome "not recovered", described as "incontinence when rising to stand and walking"; WHITE BLOOD CELL COUNT INCREASED (non-serious) with onset 26Apr2021 20:00, outcome "not recovered", described as "high wbc"; MUSCULAR WEAKNESS (non-serious) with onset 26Apr2021 20:00, outcome "not recovered", described as "leg weakness"; PARAESTHESIA (non-serious) with onset 26Apr2021 20:00, outcome "not recovered", described as "tingling in extremities"; MUSCLE TWITCHING (non-serious) with onset 26Apr2021 20:00, outcome "not recovered", described as "constant random muscle twitching spasms"; PARAESTHESIA (non-serious) with onset 26Apr2021 20:00, outcome "not recovered", described as "pins and needles hands and feet"; PERIPHERAL COLDNESS (non-serious) with onset 26Apr2021 20:00, outcome "not recovered", described as "Ice cold extremities"; HEART RATE INCREASED (non-serious) with onset 26Apr2021 20:00, outcome "not recovered", described as "elevated heart rate 105+". The events "excessive saliva production", "severe whole body muscle pain for two weeks", "still experiencing  persistent sweating 24/7", "skin irritation due to sweating", "constipation", "incontinence when rising to stand and walking", "high wbc", "leg weakness", "tingling in extremities", "constant random muscle twitching spasms", "pins and needles hands and feet", "ice cold extremities" and "elevated heart rate 105+" were evaluated at the physician office visit and emergency room visit. Relevant laboratory tests and procedures are available in the appropriate section. Therapeutic measures were taken as a result of salivary hypersecretion, myalgia, hyperhidrosis, skin irritation, constipation, incontinence, white blood cell count increased, muscular weakness, paraesthesia, muscle twitching, paraesthesia, peripheral coldness, heart rate increased.  No follow-up attempts are possible. No further information is expected.